StemCells, Inc. has announced that it has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI). The transplant was performed at the University of Miami Hospital within the Miller School of Medicine, home to The Miami Project to Cure Paralysis.
StemCells, Inc. transplants first participant in phase II clinical trial in cervical SCI
Skip back to main navigation